What Is Islet Cell Transplantation?

Islet cell transplantation is an experimental procedure for select patients with type 1 diabetes who cannot achieve stable blood glucose control despite intensive medical therapy. During the procedure, insulin-producing islets from a deceased donor pancreas are infused into the recipient’s liver via the portal vein. The islets attach to small blood vessels in the liver and begin releasing insulin in response to glucose levels. This can restore near-normal glucose regulation and reduce or eliminate the need for exogenous insulin injections. However, the procedure is not a cure: recipients must take lifelong immunosuppressive drugs to prevent rejection, which carries significant risks. Because of these risks, eligibility is restricted to those with the most severe, difficult-to-manage diabetes.

Who Is a Candidate for Islet Cell Transplantation?

Not everyone with type 1 diabetes qualifies for islet transplantation. The procedure is reserved for patients who face life-threatening complications from their disease despite optimal medical management. The basic eligibility framework includes the following core criteria:

  • Diagnosis of type 1 diabetes for at least five years – This helps confirm that the patient has true autoimmune diabetes and not a form of type 2 or monogenic diabetes that might respond to other treatments.
  • Recurrent severe hypoglycemia – Defined as episodes of low blood sugar that require third-party assistance, cause loss of consciousness, or lead to seizures. These events must occur despite intensive insulin management and continuous glucose monitoring.
  • Hypoglycemia unawareness – Many candidates demonstrate reduced or absent warning symptoms of low blood glucose, placing them at high risk for dangerous events.
  • Labile glucose levels – Wide swings between hyperglycemia and hypoglycemia that are not responsive to standard therapy. This often manifests as a high standard deviation in glucose readings or a dangerously low time-in-range.
  • Age between 18 and 65 years – While some centers may extend the upper or lower limits, most programs restrict transplantation to adults because of the risks of immunosuppression and the need for long-term compliance.

When Other Treatments Have Failed

Before islet cell transplantation is considered, patients should have exhausted all other advanced diabetes management options. These include continuous subcutaneous insulin infusion (insulin pumps), real-time continuous glucose monitoring (CGM), automated insulin delivery systems (hybrid closed-loop), and in some cases, islet or pancreas transplantation. Eligibility typically requires documentation that such therapies have been tried and have not eliminated severe hypoglycemia or achieved acceptable glycemic stability.

Body Mass Index and General Health

Candidates must have a body mass index (BMI) below a certain threshold (often 30 kg/m²) to reduce surgical risk and improve islet graft survival. They should also be free from active infections, malignancies, or other conditions that could be worsened by immunosuppression. Pre-existing heart disease, stroke, or advanced diabetic complications such as kidney failure may disqualify a patient unless they are evaluated on a case-by-case basis.

The Medical Evaluation Process

Potential recipients undergo an extensive pre-transplant workup over several weeks. The goal is to identify any contraindications and ensure the patient can tolerate the procedure and the lifelong medication regimen. The evaluation includes multiple components:

Blood Work and Laboratory Tests

  • Kidney function – Serum creatinine, estimated glomerular filtration rate (eGFR), and urine albumin-to-creatinine ratio. Impaired renal function is a relative contraindication because immunosuppressive drugs (especially calcineurin inhibitors) can accelerate kidney damage.
  • Liver function – Transaminases (AST, ALT), bilirubin, and coagulation profile. A healthy liver is essential since the infusion procedure carries a risk of bleeding or portal vein thrombosis.
  • Infection screening – HIV, hepatitis B and C, cytomegalovirus (CMV), Epstein-Barr virus (EBV), tuberculosis, and syphilis. Active infections must be treated before transplantation.
  • Autoantibody profile – Detection of GAD65, IA-2, and insulin autoantibodies to confirm type 1 diabetes and assess disease activity.
  • C-peptide level – Measured both fasting and after a mixed-meal stimulation test. Undetectable or very low C-peptide confirms absolute insulin deficiency, which is typical for transplant candidates.

Cardiovascular and Pulmonary Assessment

Because patients with long-standing diabetes often have silent cardiac disease, a thorough cardiovascular evaluation is mandatory. This includes an electrocardiogram (ECG), echocardiogram, stress testing (exercise or pharmacological), and, for those at high risk, coronary angiography. Pulmonary function tests may be ordered if there is a history of smoking or lung disease.

Imaging Studies

An abdominal ultrasound or CT scan of the liver is performed to evaluate anatomy and rule out fatty liver disease, hemangiomas, or other lesions that could complicate the infusion. A Doppler study of the portal vein is also done to confirm patency and adequate blood flow.

Psychosocial and Behavioral Evaluation

This is a critical component often overlooked. A psychologist or psychiatrist assesses the candidate’s mental health, support network, coping skills, and ability to adhere to a complex lifelong regimen. Key areas of focus include:

  • History of substance abuse (including alcohol, tobacco, and illicit drugs) – Active substance use is a contraindication due to poor compliance and increased risk of infection.
  • History of psychiatric disorders – Untreated depression, anxiety, or personality disorders that interfere with medical follow-up may disqualify a patient until adequately treated.
  • Understanding of risks and benefits – The patient must demonstrate realistic expectations about the procedure and the need for immunosuppression.
  • Social support – A partner, family member, or friend should be available to assist during the recovery period and with ongoing monitoring.

Exclusion Criteria: Who Should Not Have This Procedure?

Certain medical and lifestyle factors serve as absolute or relative contraindications to islet cell transplantation. These criteria are in place to protect patients from harm and to optimize the use of scarce donor organs.

Absolute Contraindications

  • Active malignancy (except for certain treated skin cancers) – Immunosuppression can accelerate cancer growth and spread.
  • Active infection (HIV, hepatitis B or C with active replication, untreated tuberculosis) – Potential for fatal opportunistic infections after transplantation.
  • Severe organ failure (for example, end-stage kidney, liver, or heart disease) – The patient may not survive the procedure or the organ failure could worsen with immunosuppression.
  • Known allergy to immunosuppressive drugs (tacrolimus, sirolimus, mycophenolate mofetil, etc.)
  • Inability to comply with follow-up care – This includes lack of transportation, cognitive impairment, or unwillingness to take medications.
  • Current pregnancy or plans to conceive within one year – Immunosuppressive drugs are teratogenic.

Relative Contraindications

  • Older age (>65 years) – Higher surgical risk and reduced likelihood of long-term graft survival.
  • Obesity (BMI >30 kg/m²) – Increased risk of complications and reduced islet engraftment.
  • Previous solid organ transplant – May be possible, but requires careful coordination of immunosuppressive regimens.
  • High panel-reactive antibodies (PRA) – Indicates pre-existing sensitization to donor antigens, making cross-matching difficult and rejection more likely.
  • Poorly controlled autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc.) – These can flare after transplantation.

The Role of Hypoglycemia Unawareness

One of the most compelling reasons to pursue islet cell transplantation is the presence of hypoglycemia unawareness. In normal physiology, falling blood glucose triggers a cascade of autonomic symptoms (sweating, shakiness, palpitations, hunger, anxiety). After years of diabetes and repeated hypoglycemic episodes, the body’s counter-regulatory response can become blunted. Patients lose the ability to sense low glucose levels until they are dangerously low, leading to seizures, coma, or even death. Islet transplantation can restore glucose sensing by providing a source of endogenous insulin secretion that is regulated by glucose levels, thereby also restoring some degree of hypoglycemia awareness. For patients who have suffered life-threatening episodes despite using advanced insulin pumps and CGM, this benefit can be transformative.

Age Considerations and Long-Term Outlook

Age limits are not rigid, but they are guided by several factors. Younger patients (under 18) are rarely considered because of the need for immunosuppression throughout life and the higher cumulative risk of infections, malignancy, and drug side effects. Additionally, children are more likely to have residual insulin secretion, so the risk-benefit ratio does not favor transplantation. Older adults (over 65) are also carefully evaluated: while they may have fewer years of immunosuppression exposure, they face higher surgical risks and may have more comorbidities. Some centers have performed successful transplants in patients older than 65, but only when they are exceptionally fit. The goal is to select patients who have a reasonable chance of benefiting from the graft for at least five years.

Donor Availability and Matching

Even a fully eligible candidate must wait for a suitable donor organ. Islets are usually isolated from a single donor pancreas, but because islet yield can be low, some patients receive islets from two or more donors. The waiting time depends on blood type matching (ABO compatibility), cross-match results, and the candidate’s priority status based on disease severity. In the United States, islet transplantation is performed under an Investigational New Drug (IND) protocol or as part of a clinical trial, so not all transplant centers offer it. Candidates are typically listed with the Organ Procurement and Transplantation Network (OPTN) via participating centers. The number of donor pancreases available for islet isolation is limited, which further restricts access. Research efforts are ongoing to improve islet isolation techniques and to use islets from hearts-beating donors (donation after circulatory death) or to create islets from stem cells, but these are not yet clinically available for widespread transplantation.

Risks and Benefits of Islet Cell Transplantation

Understanding the full spectrum of risks and benefits is essential for candidates and their families. The potential benefits are significant:

  • Freedom from severe hypoglycemia – Most recipients no longer experience dangerous low blood glucose episodes.
  • Improved glycemic control – Average HbA1c levels fall to near-normal range (often below 7.0%).
  • Reduced insulin requirements – Many patients become insulin-independent for one to five years, though most eventually need some insulin again as graft function declines.
  • Improved quality of life – Reduced fear of hypoglycemia, better sleep, and greater flexibility in daily life.

However, the risks are equally serious:

  • Immunosuppression side effects – Including increased risk of infections, cancers (especially skin cancer and lymphoma), kidney toxicity, hypertension, hyperlipidemia, tremor, and diarrhea.
  • Procedural risks – Bleeding, thrombosis, hepatic hemorrhage, bile leaks, and puncture of adjacent organs.
  • Graft loss – Islet function declines over time due to chronic rejection, exhaustion, or recurrence of autoimmunity. Only about 30-50% of recipients remain insulin-independent at five years.
  • Cost and access – The procedure is not yet covered by most insurance plans, and patients may face out-of-pocket costs and travel to a specialized center.

How to Determine If You Might Qualify

If you or a loved one has type 1 diabetes and is struggling with severe hypoglycemia or extreme glucose variability, the first step is to have a thorough discussion with your endocrinologist. They can help determine whether you meet the basic eligibility criteria and refer you to a transplant center. Many patients are unaware that islet transplantation exists as an option, so advocacy and education are important. The American Diabetes Association provides general guidance, and you can search for participating centers on JDRF or ClinicalTrials.gov. It is also helpful to connect with patient support groups to hear firsthand accounts.

Future Directions and Research

Islet cell transplantation continues to evolve. Newer immunosuppressive regimens aim to reduce toxicity while preserving graft function. Techniques such as islet encapsulation (coating islets in a protective gel) could one day eliminate the need for immunosuppression. Also, advances in stem cell-derived islets (like those from ViaCyte and Vertex Pharmaceuticals) hold promise for an unlimited supply of transplantable cells. For now, however, eligibility remains tightly controlled, and the procedure is best viewed as a therapeutic option for the most severe cases of type 1 diabetes.

Conclusion

Understanding the eligibility criteria for islet cell transplantation is the first step for patients with severe type 1 diabetes who are seeking alternatives to conventional therapy. The criteria are designed to select patients who will derive the greatest benefit while minimizing harm. A comprehensive medical and psychosocial evaluation ensures that candidates are prepared for the rigors of the procedure and lifelong immunosuppression. While not suitable for everyone, islet transplantation offers the possibility of dramatically improved glucose control and freedom from life-threatening hypoglycemia. If you think you might qualify, consult with a specialized transplant center to discuss your options and begin the evaluation process. For more detailed information, the National Institute of Diabetes and Digestive and Kidney Diseases and the Organ Procurement and Transplantation Network are excellent resources.